The Development and Use of T Cell Receptor Peptide Vaccines

  • Steven Brostoff
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 383)


Autoreactivity is a normal feature of the immune system which must be able to distinguish self from non-self. However, when this autoreactivity results in pathological tissue damage, autoimmune diseases result. While autoimmune diseases can be associated with autoreactive T cells or autoantibodies, many of the major autoimmune diseases are considered to be T cell mediated. These include rheumatoid arthritis, multiple sclerosis, psoriasis and type I diabetes. In developing strategies to treat T cell mediated autoimmune disease conditions, one can consider the autoreactive T cells as pathogens. Thus, one can approach therapies for T cell mediated autoimmune disease by using strategies similar to those used to control other pathogens, such as virus or bacteria. These include strategies involving immunization with attenuated or subunit forms of these pathogens.


Rheumatoid Arthritis Experimental Autoimmune Encephalomyelitis Cell Receptor Myelin Basic Protein Experimental Allergic Encephalomyelitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ben-Nun A, Wekerle H, Cohen IR. Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein. Nature 1981; 292:60–61.PubMedCrossRefGoogle Scholar
  2. 2.
    Acha-Orbea H, Mitchell DJ, Timmermann L, Wraith DC, Tausch GS, Waldor MK, Zamvil SS, McDevitt HO, Steinman L. Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. Cell 1988; 54:263–273.PubMedCrossRefGoogle Scholar
  3. 3.
    Urban JL, Kumar V, Kono DH, Gomez C, Horvath SJ, Clayton J, Ando DG, Sercarz EE, Hood L. Restricted use of T cell receptor V genes in murine autoimmune encephalomyelitis raises possibilities for antibody therapy. Cell 1988; 54:577–592.PubMedCrossRefGoogle Scholar
  4. 4.
    Burns FR, Li X, Shen N, Offner H, Chou YK, Vandenbark AA, Herber-Katz E. Both rat and mouse T cell receptors specific for the encephalitogenic determinants of myelin basic protein use similar Va. or V0 chain genes even though the major histocompatibility complex and encephalitogenic determinants being recognized are different. J Exp Med 1989; 169:27–39.PubMedCrossRefGoogle Scholar
  5. 5.
    Chluba J, Steeg C, Becker A, Wekerle H, Epplen JT. T cell receptor B chain usage in myelin basic protein-specific rat T lymphocytes. Eur J Immunol 1989; 19:279–284.PubMedCrossRefGoogle Scholar
  6. 6.
    Howell MD, Winters ST, Olee T, Powell HC, Carlo DJ, Brostoff SW. Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides. Science 1989; 246:668–670.PubMedCrossRefGoogle Scholar
  7. 7.
    Brostoff SW, Howell MD. Immunoregulation of autoimmune disease by vaccination with T cell receptor peptides. Ann NY Acad Sci 1991; 636:71–78.PubMedCrossRefGoogle Scholar
  8. 8.
    Vandenbark AA, Hashim G, Offner H. Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Nature 1989; 341:541–544.PubMedCrossRefGoogle Scholar
  9. 9.
    Offner H, Hashim GA, Vandenbark AA. T cell receptor peptide therapy triggers autoregulation of experimental encephalomyelitis. Science 1991; 251:430–432.PubMedCrossRefGoogle Scholar
  10. 10.
    Howell MD, Diveley JP, Lundeen KA, Esty A, Winters ST, Carlo DJ, Brostoff SW. Limited T cell receptor β-chain heterogeneity among IL-2R+ synovial T cells suggests a role for superantigen in rheumatoid arthritis. PNAS 1991; 88:10921–10925.PubMedCrossRefGoogle Scholar
  11. 11.
    Sedgwick J, Brostoff S, Mason D. Experimental allergic encephalomyelitis in the absence of a classical delayed-type hypersensitivity reaction. J Exp Med 1987; 165:1058–1075.PubMedCrossRefGoogle Scholar
  12. 12.
    Marrack P, Kappler J. The staphylococcal enterotoxins and their relatives. Science 1990; 248:705.PubMedCrossRefGoogle Scholar
  13. 13.
    Chang JCC, Smith LR, Froning KJ, Schwabe BJ, Laxer JA, Caralli LL, Kurland HH, Karasek MA, Wilkinson DI, Carlo DJ, Brostoff SW. CD8* T cells in psoriatic lesions preferentially use T-cell receptor Vβ3 and/or Vβ13.1 genes. PNAS 1994; 91:9282–9286.PubMedCrossRefGoogle Scholar
  14. 14.
    Chang JCC, Smith LR, Froning KJ, Schwabe BJ, Kurland HH, Karasek MA, Wilkinson DI, Carlo DJ, Brostoff SW. Unpublished data.Google Scholar
  15. 15.
    Abe J, Takeda T, Watanabe Y, Nakao H, Kobayashi N, Leung DYM, Kohsaka T. Evidence for superantigen production by Yersinia pseudotuberculosis. J Imunol 1993; 151:4183–4188.Google Scholar
  16. 16.
    Uchiyama T, Miyoshi-Akiyama T, Kato H, Fujimaki W, Imanishi K, Yan X-J. Superantigenic properties of a novel mitogenic substance produced by Yersinia pseudotuberculosis isolated from patients manifesting acute systemic symptoms. J Immunol 1993; 151:4407–4413.PubMedGoogle Scholar
  17. 17.
    Gold D, Wilson D, Smith R. Unpublished data.Google Scholar
  18. 18.
    Moreland LW, Heck LW Jr, Koopman WJ, Saway PA, Adamson TC, Fronek Z, O’Connor RD, Morgan EE, Diveley EE, Chieffo NM, Freeman TD, Carlo DJ, Brostoff SW. vp17 T Cell Receptor Peptide Vaccine: Results of a Phase I Dose-Finding Study in Patients with Rheumatoid Arthritis. Ann NY Acad Sci, in press.Google Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • Steven Brostoff
    • 1
  1. 1.The Immune Response CorporationCarlsbadUSA

Personalised recommendations